抗氧化剂与醛糖还原酶抑制剂治疗糖尿病神经源性膀胱的疗效对比被引量：5

下载PDF

导出

摘要目的观察抗氧化剂α-硫辛酸与醛糖还原酶抑制剂依帕司他治疗糖尿病神经源性膀胱的效果。方法将糖尿病神经源性膀胱患者85例随机分为3组,A组(35例)给予α-硫辛酸联合甲钴胺注射液治疗,B组(32例)给予依帕司他联合甲钴胺注射液治疗,C组(18例)仅给予甲钻胺注射液治疗,疗程均为3周。治疗前后B超测定膀胱残余尿量及行尿动力学检查。结果 3组治疗后膀胱残余尿量均较治疗前减少,差异有统计学意义(P<0.05);A、B2组膀胱初尿意容量均较治疗前减少,最大尿流率、最大尿流率时逼尿肌压力均增加,差异有统计学意义(P<0.05),C组尿流动力学各指标治疗前后差异无统计学意义(P>0.05);治疗后A组膀胱残余尿量、膀胱初尿意容量及最大尿流率改善程度较B组明显,差异有统计学意义(P<0.05)。A组治疗总有效率85.7%,明显高于B、C组的50.0%,差异有统计学意义(P<0.05)。结论α-硫辛酸及依帕司他治疗糖尿病神经源性膀胱均有效,其中硫辛酸疗效显著。

作者王丽娜郭玉卿康岩周慧敏刘璠

机构地区河北医科大学第一医院内分泌科

出处《河北医科大学学报》 CAS 2014年第5期568-570,共3页 Journal of Hebei Medical University

关键词糖尿病神经源病变抗氧化剂醛糖还原酶

分类号 R587.25 [医药卫生—内分泌]

引文网络
相关文献

参考文献9

1郑恂,镇奋,段跃.α-硫辛酸联合莫沙必利治疗糖尿病神经源性膀胱的临床研究[J].中国基层医药,2013,20(11):1620-1621. 被引量：4
2CHANG s,HYPOLITE JA, MOHANAN S, et al. Alteration of the PKC-mediated signaling pathway for smooth muscle contraction in obstruction-induced hypertrophy of the urinary bladder [ J ]. Lab Invest,2009,89(7) :823 -832.
3DONN J, LEDGER A. An update on the treatment and management of diabetic peripheral neuropathy[ J ]. Cannt J ,2006,16 (4) : 32 - 38.
4HEAD KA. Peripheral neuropathy: pathogenic mechanisms and alternative therapies [ J ]. Altem Med Rew, 2006,11 ( 4 ) : 294 - 329.
5梅花,李小飞.前列腺素E1联合硫辛酸治疗糖尿病周围神经病变疗效观察[J].中国卫生产业,2007(07X):101-101. 被引量：3
6SEKIDO H, SUZUKI T, JOMORI T, et al. Rudueed cell replication and induction of apoptosis by advanced glycation end products in rat schwann cells [ J ]. Biodem Biophys Res Commum, 2004,320 ( 1 ) :241 -248.
7邱轩,刘宽芝.糖尿病神经病变及神经性疼痛的治疗进展[J].河北医科大学学报,2012,33(11):1351-1354. 被引量：7
8王述进,李俊枝,左红,周克斌,杨勇,赵留存.尿流动力学检查在糖尿病神经源性膀胱诊断中的意义[J].现代医学,2005,33(6):382-383. 被引量：6
9王云汉,杨进.糖尿病膀胱病研究进展[J].现代临床医学,2012,38(2):83-84. 被引量：9

二级参考文献38

1付艳芹,张东铭,辛雅萍,张苏河.α-硫辛酸对糖尿病周围神经病变的疗效及对氧化应激的影响[J].中国实用神经疾病杂志,2010,13(23):70-71. 被引量：18
2PARO M ,PROSDOCIMI M, ZHANG W X, et al.A possible role for nerve growth factor in the pathogenesis of diabetic neuropathy[J]. Diabetes, 1989,88: 1023-1030.
3FLYNN M D, TOORE J E. Diabietic nellropathy and the microcircalation [J]. Diabet Med, 1995,12:298.
4PARO M, PRASHAR A, PROSDOCIMI M, et al.Urinary bladder dysfunction in the BB/W diabetic rat:effect of ganglioside treatment on functional and structural alterations[J]. J Urol, 1994, 151: 781-786.
5Lee WC, Wu HP, Tai TY, et al. Effects of diabetes on female voiding behavior[J]. J Urol,2004,17(2) :989.
6Chang S, Hypolite JA, Mohanan S, et al. A. Alteration of the PKC - mediated signaling pathway for smooth muscle contraction in obstruction -induced hypertrophy of the urinary bladder[ J ]. Lab Invest,2009,89 (7) : 823 - 832.
7Kamata K, Inoue Kasuya Y. Changes incontractile responses of the urinary bladder to substance P in streptozotocin - induced diabetic rats [ J ]. Gen Pharmacol, 1993,24 ( 3 ) : 547 - 553.
8Pak K J, Ostrom RS, Matsui M, et al. Impaired M3 and enhanced M2 muscarinic receptor contractile function in a streptozotocin model of mouse diabetic urinary bladder [ J ]. Naunyn Schmiedebergs Arch Pharmaeol,2010,381 (5) :441 -454.
9Tammela TL, Briscoe JA, Levin RM, et al. Factors underlying the increased sensitivity to field stimulation of urinary bladder strips from streptozotocin - induced diabetic rats [ J ]. Br J Pharmacol, 1994, 113 (1) :195 -203.
10Pak K J, Ostrom KS, Matsui M,et al. Ehlert,Impaired M3 and enhanced M2 muscarinic receptor contractile function in a streptozotocin model of mouse diabetic urinary bladder [ J ]. Naunyn Schmiedebergs Arch Pharmacol,2010,381 (5) :441 -454.